Strategic timing Leverage the upcoming termination of PEMGARDA EUA in June 2027 to engage customers on transitioning from EUA to alternative preventive solutions, positioning Invivyd as a partner for long-term COVID-19 protection strategies.

Phase 3 momentum Capitalise on LIBERTY trial enrollment and expected Q3 2026 topline data to engage health systems and payers with evidence on VYD2311 safety, tolerability, and potential to complement or substitute vaccines in specific populations.

Portfolio differentiation Highlight the antibody-based prevention approach as a distinct alternative to vaccines, targeting immune-compromised populations, which may open cross-sell opportunities with specialty clinics, infectious disease networks, and immunology centers.

Expansion potential With a mid-sized workforce and ongoing trials, identify partnerships or sponsored studies with academic medical centers and contract research organizations to accelerate enrollment, data generation, and market access strategies.

Evidence-driven engagement Utilize LIBERTY and DECLARATION study results to craft value propositions for payers and providers around reduced hospitalization risk, patient quality of life, and potential cost savings, driving discussions on reimbursement pathways.